Abstract | PURPOSE: METHODS: RESULTS: The median number of injections was 3 with a median follow-up of 17 months. The median visual acuity at baseline was 20/100 and improved to 20/50 at final examination (P < 0.0001). Best-corrected visual acuity improved by > or = 3 lines in 15 of 32 eyes (46.8%). The median central thickness was 336 microm (range, 179-663 microm) at baseline and 233 microm (range, 125-465 microm) at final examination (P < 0.0001). No severe drug-related side effect was reported. CONCLUSION:
|
Authors | Franck Lalloum, Eric H Souied, Sylvie Bastuji-Garin, Nathalie Puche, Giuseppe Querques, Agnes Glacet-Bernard, Gabriel Coscas, Gisele Soubrane, Nicolas Leveziel |
Journal | Retina (Philadelphia, Pa.)
(Retina)
Vol. 30
Issue 3
Pg. 399-406
(Mar 2010)
ISSN: 1539-2864 [Electronic] United States |
PMID | 20038864
(Publication Type: Journal Article)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Coloring Agents
- Indocyanine Green
- Ranibizumab
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors
(administration & dosage, therapeutic use)
- Antibodies, Monoclonal
(administration & dosage, therapeutic use)
- Antibodies, Monoclonal, Humanized
- Choroidal Neovascularization
(diagnosis, drug therapy, etiology)
- Coloring Agents
- Female
- Fluorescein Angiography
- Follow-Up Studies
- Humans
- Indocyanine Green
- Injections
- Male
- Middle Aged
- Myopia, Degenerative
(complications)
- Prospective Studies
- Ranibizumab
- Tomography, Optical Coherence
- Treatment Outcome
- Visual Acuity
- Vitreous Body
|